restrictive cardiomyopathy: A type of heart disorder referring to the inability of the ventricles to fill with blood because the myocardium (heart muscle) stiffens and looses its flexibility. Causes include replacement of the myocardium with scar tissue, abnormal cellular infiltration of the myocardium, or deposition of a substance (e.g., amyloid) in the myocardium.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
126 |
4. Check minimum number of eventsNone |
126 |
5. Include endpointsNone |
126 |
6. Filter based on genotype QC (FinnGen only) |
120 |
Control definitions (FinnGen only)
- Control exclude
- I9_CARDMYO
Extra metadata
- Level in the ICD hierarchy
- C
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- I42
- Name in latin
- Cardiomyopathia restrictiva
Similar endpoints
↥List of similar endpoints to
Restrictive cardiomyopathy
based on the number of shared cases.
Similar with more cases:
- Cardiomyopathies, Primary/intrinsic
- Cardiomyopathy (excluding other)
- Cardiomyopathy
- Other heart diseases
- Other heart diseases, wide
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 790 | 397 | 379 |
| Only index persons | 553 | 298 | 255 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 68.55 | 72.32 | 64.68 |
| Only index persons | 70.21 | 73.52 | 66.34 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 120 | 53 | 67 |
| Unadjusted period prevalence (%) | 0.03 | 0.02 | 0.03 |
| Median age at first event (years) | 67.33 | 70.78 | 64.60 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 126
- Matched controls
- 1260
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
I42.5
ICD-10 Finland
Other restrictive cardiomyopathy
+∞
163.9
119
*
C03DA01
ATC
spironolactone; oral
25.7
79.9
84
91
I50.9
ICD-10 Finland
Heart failure, unspecified
21.4
67.1
94
152
201
Kela drug reimbursment
Chronic cardiac insufficiency
22.1
54.0
46
32
I50.0
ICD-10 Finland
Congestive heart failure
14.8
51.5
63
80
C03CA01
ATC
furosemide; systemic
23.4
44.9
113
341
B01AA03
ATC
warfarin; systemic
11.9
44.6
83
176
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
10.6
40.8
77
163
TFC00
NOMESCO Finland
Catheterisation of right atrium or ventricle
546.4
40.5
38
*
FN1AC
NOMESCO Finland
Angiography of heart and/or coronary arteries
10.2
38.8
83
200
I42.9
ICD-10 Finland
Cardiomyopathy, unspecified
+∞
38.5
35
*
I42.0
ICD-10 Finland
Dilated cardiomyopathy
+∞
35.0
32
*
XFP20
NOMESCO Finland
Check up of cardiac pacemaker
12.1
31.5
37
42
TFP20
NOMESCO Finland
Cardiodefibrillation
10.6
31.4
42
57
I48
ICD-10 Finland
Atrial fibrillation and flutter
8.1
31.1
80
223
AN1
HP
Coronary angiography
8.8
30.0
50
88
Z95.0
ICD-10 Finland
Presence of electronic cardiac devices
13.4
29.2
31
30
FM1BE
NOMESCO Finland
Cardiac ultrasound examination through oesophagus
11.7
28.2
33
37
C01AA05
ATC
digoxin; systemic
8.5
26.7
43
72
207
Kela drug reimbursment
Chronic arrhythmias
6.7
24.9
58
142
FXA00
NOMESCO Finland
Total cardiopulmonary bypass in normothermia or moderate hypothermia at concurrent surgical procedure
12.0
24.1
27
28
M04AA01
ATC
allopurinol; systemic
6.5
22.9
52
123
FJA10
NOMESCO Finland
Transvenous biopsy of right ventricle
+∞
20.4
19
*
K78
ICPC
Atrial fibrillation/flutter
7.3
20.0
35
63
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
8.5
19.1
28
41
C07AB07
ATC
bisoprolol; oral
6.9
18.4
104
512
Z45.0
ICD-10 Finland
Adjustment and management of cardiac devices
25.6
18.2
25
12
FM1DG
NOMESCO Finland
Very extensive MRI examination of heart with high intesity magnet
49.8
17.9
21
5
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
5.2
17.7
51
145
M10.9
ICD-10 Finland
Gout, unspecified
7.1
16.2
28
49
WX892
NOMESCO Finland
Monitored bed care
7.2
16.0
27
46
Z94.1
ICD-10 Finland
Heart transplant status
181.6
15.9
16
*
XF404
NOMESCO Finland
Ambulatory ECG
6.0
15.8
33
70
GD1AA
NOMESCO Finland
Thorax X-ray examination
5.1
15.7
94
460
Z2221
NOMESCO Finland
Medical doctor
4.5
15.6
62
224
XF400
NOMESCO Finland
ECG with 12 standard connections
4.6
15.0
49
152
TFJ02
NOMESCO Finland
Muscle biopsy of heart
91.0
14.9
16
*
I42.2
ICD-10 Finland
Other hypertrophic cardiomyopathy
+∞
14.9
14
*
I36.1
ICD-10 Finland
Nonrheumatic tricuspid (valve) insufficiency
24.5
13.8
19
9
127
Kela drug reimbursment
Transplant complication
29.7
13.8
18
7
I27.2
ICD-10 Finland
Other secondary pulmonary hypertension
+∞
13.8
13
*
I50.1
ICD-10 Finland
Left ventricular failure
10.9
13.0
25
28
GA4YT
NOMESCO Finland
Puncture of pleura with ultrasound guidance
14.6
12.7
21
17
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
6.3
12.3
23
43
C01BD01
ATC
amiodarone; systemic
17.0
12.2
19
13
290
Kela drug reimbursment
Apixaban, dabigatran, edoxaban and rivaroxaban for the treatment of atrial fibrillation
4.1
12.1
45
151
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
4.5
11.9
36
103
L04AD02
ATC
tacrolimus; systemic
39.0
11.5
14
*
L04AA06
ATC
mycophenolic acid; systemic
28.1
11.4
15
6
R06.0
ICD-10 Finland
Dyspnoea
3.6
11.3
60
254
I48.9
ICD-10 Finland
Atrial fibrillation and atrial flutter, unspecified
6.4
11.1
20
36
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
3.6
10.9
56
231
J18.9
ICD-10 Finland
Pneumonia, unspecified
3.5
10.8
58
246
R4110
NOMESCO Finland
Physiotherapy
3.5
10.8
60
260
I50
ICD-10 Finland
Heart failure
11.1
10.7
20
21
I42.1
ICD-10 Finland
Obstructive hypertrophic cardiomyopathy
+∞
10.6
10
*
TFP34
NOMESCO Finland
Electrophysiological investigation
35.9
10.6
13
*
TFB00
NOMESCO Finland
Cathetrisation of pulmonal artery
35.9
10.6
13
*
Z3231
NOMESCO Finland
Registered nurse
3.4
10.4
63
287
81
HP
Angiography of the heart and coronary arteries
5.2
10.3
24
55
351
Kela drug reimbursment
Apixaban, dabigatran, edoxaban and rivaroxaban for the treatment of atrial fibrillation
3.8
10.0
39
133
G04BE03
ATC
sildenafil; oral
23.9
9.6
13
6
WX740
NOMESCO Finland
Nitrogen oxide therapy
+∞
9.5
9
*
4250A
ICD-9 Finland
Cardiomyopathy, Endomyocardial fibrosis
+∞
9.5
9
*
I42.8
ICD-10 Finland
Other cardiomyopathies
+∞
9.5
9
*
A10BK01
ATC
dapagliflozin; oral
5.7
9.4
19
38
ZXD05
NOMESCO Finland
Urgent procedure
3.2
8.9
53
234
WX872
NOMESCO Finland
Intensive care
7.7
8.8
20
30
FN1BC
NOMESCO Finland
Extensive angiography of hear and/or coronary arteries
5.5
8.7
18
37
4273A
ICD-9 Finland
Cardiac dysrhythmias, Atrial fibrillation and flutter
21.9
8.6
12
6
B01AF02
ATC
apixaban; oral
3.7
8.4
31
101
ZXE10
NOMESCO Finland
More than one and less than three hours
2.9
8.2
63
319
GD1LA
NOMESCO Finland
GD
23.9
8.2
11
5
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
3.0
8.1
54
252
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
3.6
8.0
31
104
N17.9
ICD-10 Finland
Acute renal failure, unspecified
9.0
7.9
16
20
ZXD10
NOMESCO Finland
Scheduled procedure
2.9
7.8
66
350
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
5.0
7.7
18
41
I48.2
ICD-10 Finland
Chronic atrial fibrillation
6.6
7.6
19
33
C07AG02
ATC
carvedilol; oral
4.7
7.6
19
46
R18
ICD-10 Finland
Ascites
14.6
7.6
12
9
KA1MN
NOMESCO Finland
Glomerular filtration rate (GFR) Isotope mesurement
84.9
7.5
8
*
H02AB06
ATC
prednisolone; systemic
2.8
7.5
76
440
C09AA05
ATC
ramipril; oral
2.8
7.5
56
277
FQA10
NOMESCO Finland
Orthotopic transplantation of heart with bicaval anastomosis
+∞
7.4
7
*
FQA00
NOMESCO Finland
Orthotopic transplantation of heart
+∞
7.4
7
*
XF620
NOMESCO Finland
Examination of circulation with color method
+∞
7.4
7
*
FPE20
NOMESCO Finland
Implantation of transvenous cardiac pacemaker with atrial and ventricular electrodes
8.8
7.3
15
19
ZXE00
NOMESCO Finland
One hour or less
2.8
7.3
67
366
JA3AT
NOMESCO Finland
Cathetrisation of abdominal cavity with ultrasound guidance
21.5
7.3
10
5
TK800
NOMESCO Finland
Hemodialysis
13.1
7.2
12
10
K84
ICPC
Heart disease other
11.0
7.2
13
13
C10AA01
ATC
simvastatin; oral
2.8
7.2
77
455
Z01.8
ICD-10 Finland
Other specified special examinations
3.1
7.1
36
143
ZX120
NOMESCO Finland
Intravenous
3.6
6.9
26
85
Z03.5
ICD-10 Finland
Observation for other suspected cardiovascular diseases
4.1
6.8
20
55
TPH04
NOMESCO Finland
Cathetrisation of vein
2.9
6.7
41
180
A12BA01
ATC
potassium chloride; oral
4.4
6.7
18
46
AP1
HP
Catheterization of the left side of the heart
10.9
6.7
12
12
I44.2
ICD-10 Finland
Atrioventricular block, complete
8.1
6.6
14
19
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
3.6
6.6
24
77
I48.1
ICD-10 Finland
Persistent atrial fibrillation
6.6
6.6
16
27
AP3
HP
Catheterization of the right and left side of the heart
73.4
6.5
7
*
AP2
HP
Catheterization of the right side of the heart
73.4
6.5
7
*
JN3AD
NOMESCO Finland
Abdominal CT examination
3.6
6.4
24
78
R02
ICPC
Shortness of breath/dyspnoea
3.3
6.4
27
95
AP4
HP
Myocardial biopsy
+∞
6.3
6
*
I27.0
ICD-10 Finland
Primary pulmonary hypertension
+∞
6.3
6
*
I63.4
ICD-10 Finland
Cerebral infarction due to embolism of cerebral arteries
6.7
6.2
15
25
JN4AD
NOMESCO Finland
Body CT examination
3.5
6.2
24
80
Z95.2
ICD-10 Finland
Presence of prosthetic heart valve
13.4
6.2
10
8
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
3.7
6.0
21
65
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
99
360
9.17
28.74
14.3
3.1
3802.41
1751.88
ng/l
1.94
93
308
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
28
36
9.71
21.32
12.2
3.4
0.34
0.34
u/ml
0.01
16
21
57
175
5.12
18.11
5.0
2.4
2.40
2.35
g/l
0.29
52
159
28
52
6.64
15.27
2.2
1.9
1.36
1.52
g/l
0.33
23
44
67
274
4.09
13.87
4.0
2.1
2.97
3.26
mg/l
0.52
55
239
20
35
6.60
11.41
9.3
4.2
84.50
89.60
%
0.56
20
35
43
150
3.83
10.78
11.3
6.2
102.93
103.75
mmol/l
0.44
43
150
62
275
3.47
10.75
5.2
2.9
415.56
10906.08
umol/l
1.85
52
229
94
552
3.77
10.13
18.3
6.8
1.19
1.21
mmol/l
2.86
87
467
38
127
3.85
10.07
2.5
1.8
—
—
—
0
0
91
526
3.63
10.01
63.2
14.3
1.67
1.31
inr
1.71
23
161
75
393
3.24
9.56
5.9
2.8
148.20
145.84
ug/l
0.04
69
353
37
129
3.64
9.14
2.6
1.8
—
—
—
0
0
83
470
3.24
9.11
8.4
4.5
34.02
34.95
g/l
0.76
78
437
45
182
3.29
8.77
2.8
1.9
—
—
—
0
0
20
31
7.46
8.61
5.2
3.3
187.55
198.65
%
0.18
20
31
20
46
4.98
8.50
3.5
2.1
—
—
—
0
0
15
16
10.47
8.04
2.0
1.3
10284.10
37425.00
e6/l
—
10
8
16
21
8.55
7.67
2.5
1.1
—
—
—
0
0
15
18
9.29
7.57
2.0
1.3
464.80
1045.31
e6/l
—
10
13
42
177
3.06
7.50
7.7
2.5
32.04
30.09
s
1.18
42
172
58
297
2.77
7.18
4.3
2.0
192.87
289.60
u/l
0.42
52
278
15
20
8.35
7.14
2.1
1.5
—
—
—
0
0
51
246
2.80
7.06
4.8
2.2
—
—
—
0
0
34
131
3.19
7.03
21.3
7.9
0.54
1.17
mmol/l
0.29
29
109
76
453
2.71
6.87
8.5
3.8
101.19
53.75
ng/l
0.33
63
334
47
225
2.74
6.52
5.3
1.9
1.10
1.32
mg/l
0.40
42
181
25
83
3.51
6.51
1.6
1.6
—
—
—
0
0
16
39
4.55
6.30
21.5
6.3
2.08
1.59
mg/l
0.75
16
34
17
33
5.79
6.29
7.8
3.7
91.34
105.43
mg/l
0.09
17
25
17
33
5.79
6.29
7.8
3.8
32.31
27.82
mg/l
0.31
17
25
70
418
2.52
6.06
5.0
3.3
—
—
—
0
0
61
347
2.47
5.80
3.4
3.4
2.34
2.36
mmol/l
0.28
53
295
58
326
2.44
5.62
5.0
3.2
1.14
0.45
e6/l
1.18
50
245
20
63
3.58
5.60
2.6
1.6
—
—
—
0
0
14
25
6.16
5.56
1.4
1.6
—
—
—
0
0
14
25
6.16
5.56
1.4
1.6
—
—
—
0
0
9
8
11.99
5.38
1.0
1.4
—
—
—
0
0
91
636
2.55
5.31
15.7
9.8
4.48
4.24
e9/l
0.40
81
544
24
97
2.82
4.45
39.4
6.4
24.83
24.79
mmol/l
0.02
24
97
10
16
6.68
4.39
1.3
1.3
135.90
180.04
u/l
—
10
16
21
81
2.91
4.23
10.1
4.3
2.46
1.97
mmol/l
0.26
14
53
66
429
2.13
4.19
2.4
2.0
92.20
96.15
pmol/l
0.31
37
200
12
26
4.99
4.18
1.1
1.2
—
—
—
0
0
13
33
4.27
3.93
1.3
1.2
—
—
—
0
0
39
211
2.23
3.90
3.3
3.4
2.46
2.47
mmol/l
0.30
34
181
37
196
2.26
3.89
4.3
2.8
2.29
0.91
e6/l
0.75
20
110
40
219
2.21
3.88
1.8
1.7
1219.74
1186.38
nmol/l
0.07
34
166
18
67
2.97
3.85
5.0
4.4
54.90
57.55
ml/min/173m2
—
10
29
16
58
3.01
3.57
9.3
3.3
0.63
0.70
%
0.35
16
58
6
6
10.41
3.53
1.2
1.2
—
—
—
0
0
9
18
5.30
3.44
1.2
1.2
—
—
—
0
0
8
14
6.02
3.40
1.1
1.6
—
—
—
0
0
16
60
2.91
3.37
9.3
3.3
1.06
1.19
%
0.30
16
60
10
24
4.43
3.27
1.6
1.6
—
—
—
0
0
95
752
2.07
3.10
8.1
4.1
15.71
13.57
mm/h
0.80
89
679
6
8
7.80
3.09
1.3
2.5
—
—
—
0
0
5
5
10.33
3.00
1.8
1.2
—
—
—
0
0
7
14
5.22
2.77
1.1
1.6
—
—
—
0
0
34
197
1.99
2.76
4.8
3.0
2.76
1.34
e6/l
0.85
17
111
67
489
1.79
2.63
5.5
2.5
—
—
—
0
0
8
20
4.20
2.61
1.5
1.7
—
—
—
0
0
10
31
3.41
2.58
1.3
1.7
—
—
—
0
0
10
31
3.41
2.58
1.7
1.5
—
—
—
0
0
11
37
3.16
2.56
1.8
1.6
—
—
—
0
0
7
16
4.56
2.51
1.0
1.3
—
145.64
—
0
5
10
32
3.30
2.50
1.3
1.4
—
—
—
0
0
5
8
6.45
2.39
5.4
1.3
3.58
2.87
mg/l
—
5
8
10
34
3.10
2.34
1.7
1.5
—
—
—
0
0
6
14
4.44
2.17
2.8
1.5
—
—
—
0
0
6
14
4.44
2.17
1.3
1.9
—
—
—
0
0
6
14
4.44
2.17
1.3
1.9
—
—
—
0
0
6
15
4.14
2.06
2.3
2.5
21.00
15.89
ug/l
—
6
15
7
21
3.47
1.99
1.3
1.6
—
—
—
0
0
7
21
3.47
1.99
1.3
1.6
—
—
—
0
0
6
17
3.65
1.86
2.0
1.6
—
—
—
0
0
40
274
1.67
1.84
1.8
1.6
16.95
21.53
nmol/l
1.81
34
226
5
13
3.96
1.73
2.2
2.4
—
—
—
0
0
54
410
1.55
1.60
4.2
2.4
79.51
76.10
nmol/l
0.34
49
350
6
20
3.10
1.60
1.0
1.4
—
—
—
0
0
110
999
1.80
1.37
46.0
16.1
22.42
25.67
mg/l
0.80
103
827
6
25
2.47
1.26
1.2
1.4
0.21
0.22
g/l
—
6
25
65
533
1.45
1.25
8.8
5.4
0.00
0.00
estimate
-0.00
17
103
31
219
1.55
1.23
1.4
1.4
0.28
1.06
u/ml
—
5
64
5
19
2.70
1.22
10.6
1.7
3.91
3.46
mg/l
—
5
14
6
26
2.37
1.20
1.2
1.4
1.08
1.08
g/l
—
6
26
65
537
1.43
1.18
6.0
4.0
0.00
0.00
estimate
-0.00
15
101
8
40
2.07
1.14
2.1
2.3
—
—
—
0
0
13
75
1.82
1.07
1.5
1.3
—
—
—
0
0
64
537
1.39
1.02
6.1
3.9
0.00
0.01
estimate
0.50
17
115
83
728
1.41
1.02
5.5
3.7
15.33
14.97
pmol/l
0.54
77
643
41
323
1.40
0.94
3.4
3.9
20.40
8.68
mg/mmol
0.52
30
215
6
28
2.20
0.93
2.2
1.7
—
—
—
0
0
100
917
1.44
0.87
7.3
6.5
42.56
41.45
mmol/mol
0.60
95
846
0
26
0.00
0.79
0.0
1.7
—
—
—
0
0
6
34
1.80
0.77
1.5
1.8
—
—
—
0
0
5
23
2.22
0.77
1.6
1.2
—
—
—
0
0
19
135
1.48
0.74
1.2
1.2
1.12
4.28
u/ml
—
6
49
7
42
1.71
0.69
2.7
2.0
—
—
—
0
0
7
42
1.71
0.69
2.6
1.8
—
—
—
0
0
103
965
1.37
0.64
6.0
5.3
2.27
2.62
mmol/l
3.73
98
871
8
49
1.67
0.63
1.4
2.7
13.00
290.97
u/ml
—
8
38
16
116
1.43
0.58
21.6
8.2
—
—
—
0
0
19
247
0.73
0.57
3.3
3.0
0.88
0.76
ug/l
0.23
13
155
15
111
1.40
0.49
4.8
3.8
—
—
—
0
0
35
297
1.25
0.46
5.3
4.2
0.00
0.00
estimate
-0.00
16
102
5
33
1.54
0.42
1.2
1.2
—
—
—
0
0
0
17
0.00
0.41
0.0
1.1
—
1.07
—
0
8
0
17
0.00
0.41
0.0
1.2
—
2.81
—
0
9
5
34
1.49
0.41
1.2
1.2
—
—
—
0
0
0
18
0.00
0.40
0.0
1.2
—
—
—
0
0
94
891
1.22
0.38
6.7
4.6
2.57
2.03
mu/l
1.65
88
786
96
914
1.21
0.36
44.0
16.2
60.11
75.52
ml/min/173m2
6.74
91
760
58
538
1.14
0.27
3.3
2.5
—
—
—
0
0
0
11
0.00
0.21
0.0
1.4
—
—
—
0
0
0
10
0.00
0.21
0.0
1.5
—
—
—
0
0
0
14
0.00
0.20
0.0
1.3
—
—
—
0
0
97
940
1.14
0.20
5.4
4.8
6.09
6.14
mmol/l
0.12
83
847
30
327
0.89
0.17
4.1
4.2
21.81
20.25
%
—
10
160
5
43
1.17
0.10
1.2
1.3
—
—
—
0
0
7
64
1.10
0.08
1.1
1.3
—
—
—
0
0
14
129
1.10
0.06
1.5
1.5
—
—
—
0
0
40
412
0.96
0.04
4.7
5.1
2.29
2.78
ug/l
0.21
32
366
43
418
1.04
0.04
7.1
4.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
5.8
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
3.9
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
-0.00
0.0
3.9
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
111.02
—
0
6
0
6
0.00
-0.00
0.0
1.0
—
19.00
—
0
6
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
6.27
—
0
6
0
7
0.00
-0.00
0.0
1.9
—
—
—
0
0
5
54
0.92
-0.00
1.2
1.8
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
51.78
—
0
6
0
6
0.00
-0.00
0.0
1.8
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint I9_CARDMYORESTR and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| I9_CARDMYORESTR | 3.454 [2.39, 4.98] | < 0.001 |
| Birth year | 0.996 [0.99, 1.0] | 0.374 |
During the follow-up period (1.1.1998 — 31.12.2019), 141 out of 266 females with I9_CARDMYORESTR died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| I9_CARDMYORESTR | 3.473 [2.16, 5.58] | < 0.001 |
| Birth year | 0.989 [0.98, 1.0] | 0.019 |
During the follow-up period (1.1.1998 — 31.12.2019), 110 out of 218 males with I9_CARDMYORESTR died.
Mortality risk
Mortality risk for people of age
years, who have I9_CARDMYORESTR.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.452% | 0.712% |
| 5 | 2.057% | 3.886% |
| 10 | 5.061% | 10.332% |
| 15 | 9.883% | 18.825% |
| 20 | 17.043% | 30.526% |
Relationships between endpoints
↥Index endpoint: I9_CARDMYORESTR – Restrictive cardiomyopathy
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data